Target intelligence / Profile preview

F-box and leucine-rich repeat protein 3 (FBXL3)

Target
FBXL3
Molecular classification
Enzyme (component of E3 ubiquitin-protein ligase complex, SCF-type), Ubiquitin ligase, F-box protein family, Leucine-rich repeat protein
01

Overview

F-box and leucine-rich repeat protein 3 (FBXL3) is an F-box family member featuring leucine-rich repeats, serving as the substrate-recognition element of the nuclear SCF (Skp1–Cullin–F-box) E3 ubiquitin ligase complex. FBXL3 specifically targets mammalian cryptochrome proteins (CRY1 and CRY2) for ubiquitination and degradation, thus sustaining circadian clock oscillations. Mutations in FBXL3 alter circadian rhythm speed and robustness, and are implicated in intellectual disability, epilepsy, and other developmental disorders. Small molecules such as KL001 bind to cryptochromes, protecting them from FBXL3-induced degradation, and represent a pharmacological avenue for modulating sleep and circadian disorders. FBXL3’s activity is tightly regulated by protein structure, cofactor interaction (FAD), and competitive protein-protein contacts, making it a central modulator of circadian timing and an emerging therapeutic target.

Other names
F-box/LRR-repeat protein 3FBL3AFBXL3AFBL3IDDSFASF-box and leucine-rich repeat protein 3AF-box/LRR-repeat protein 3AF-box protein Fbl3aFBXL3_HUMAN (UniProt)
02

Mechanism of action

Small molecules that stabilize CRY proteins interfere with substrate recognition by FBXL3, thereby blocking ubiquitination and prolonging the circadian period. Direct competition between small molecules, FAD, and the C-terminal tail of FBXL3 for binding cryptochrome FAD pocket.

03

Biological functions

Circadian rhythm regulation (degradation of CRY proteins)Ubiquitin-protein transferase activityProtein turnover through ubiquitinationRegulation of transcription feedback loops in cellular clocks
04

Disease associations

Intellectual developmental disorder with short stature, facial anomalies, and speech defectsEpilepsyPotential role in sleep/circadian-related disordersOther roles emerging from disruption of circadian rhythm
05

Safety considerations

Therapeutic targeting may lead to circadian rhythm disruptionPotential for unintended neurodevelopmental and metabolic side effects (as seen in gene mutation phenotypes)Off-target protein turnover due to broad participation in ubiquitin ligase complexes
06

Interacting drugs

KL001
07

Biomarkers

Null (no clinically established biomarkers for FBXL3 targeting in patient selection)

Beyond the preview

Go deeper on F-box and leucine-rich repeat protein 3 (FBXL3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on F-box and leucine-rich repeat protein 3 (FBXL3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call